DATE
September 11, 2025
VENUE
Educational and Conference Center
of the Maria Sklodowska-Curie National Research Institute of Oncology
Agenda
08:15 – 09:00
Participant Registration / Morning Coffee
09:00 – 09:30
Official Conference Opening
Welcome Remarks
Prof. Beata Jagielska – Director of Maria Sklodowska-Curie National Research Institute of Oncology, Poland
Inaugural Speeches by Representatives of the Ministry of Health and Medical Universities
Dr Agnieszka Gorgoń-Komor – Cardiologist & Senator of the Republic of Poland
Prof. Krzysztof J. Filipiak – Cardiologist & Director of the Centre of Postgraduate Medical Education
09:30 – 10:50
Plenary International Session I: | ||
| 9.30 – 9.50 | Beata Jagielska Director of Maria Sklodowska-Curie National Research Institute of Oncology | Inaugural lecture |
| 9.50 – 10.10 | Susan Dent President of the International Cardio-Oncology Society (IC-OS) | Achievements in cardio-oncology care – a perspective of the President of the International Cardio-Oncology Society |
| 10.10 – 10.30 | Raul Cordoba Mascuñano EHA liaison with the ESC | Hematologist’s view on cardio-oncology |
| 10.30 – 10.50 | Giuseppe Curigliano President Elect of the European Society for Medical Oncology (ESMO) | How to Treat Cancer Without Harming the Heart – Personalized Cancer Therapy Strategies |
11:00 – 12:00
Session II — under patronage of the Medical Research Agency | ||
| 11.00 – 11.15 | Mateusz Tajstra | Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM) |
| 11.15 – 11.30 | Ewa Lech-Marańda | A Randomized, Double‐Blind, Phase2 Trial Evaluating the Efficacy, Safety, and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation (HEART‐DAPA‐ MM) |
| 11.30 – 11.45 | Bartosz Krakowiak | A multicentre, randomised, double-blind, placebo-controlled phase III study, evaluating the effect of dapagliflozin on prevention of cardiotoxicity in breast cancer patients undergoing anthracycline-based chemotherapy – PROTECTAA TRIAL |
| 11.45 – 12.00 | Anna Borowiec | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardiotoxicity in Cancer patients undergoing Chemotherapy based on Anthracyclines – EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) |
12:00 – 12:20
Coffee break
12:20 – 14:00
Session III — under patronage of the Polish Cardiac SocietyChairs: | ||
| 12.20 – 12.40 | Teresa López Fernández Chair of the ESC Council of Cardio-Oncology (2024-2026) | Cardio-Oncology in Europe – Guidelines and Challenges |
| 12.40 – 13.00 | Peter van der Meer Chair-Elect of the ESC Council of Cardio-Oncology (2026-2028) | Cardiotoxicity beyond anthracyclines |
| 13.00 – 13.15 | Barbara Alicja Jereczek-Fossa President Elect of the European Society for Radiotherapy and Oncology (ESTRO) | Can we minimize radiotherapy-related cardiovascular toxicity? |
| 13.15 – 13.30 | Bonnie Ky Editor-in-Chief JACC Cardio-Oncology | The Best of JACC CardioOncology |
| 13.30 – 13.45 | Robert Gil President of the Polish Cardiac Society | Coronary artery disease in cardio-oncology: Perspective of an Invasive Cardiologist |
| 13.45 – 14.00 | Maciej Banach President, International Lipid Expert Panel | Lipid lowering therapy for better prognosis of cancer patients |
14:00 – 14:45
Lunch
14:45 – 16:00
Session IV — under patronage of the International Cardio-Oncology Society | ||
| 14.45 – 15.00 | Aaron Sverdlov Co-Director of Newcastle Centre of Excellence in Cardio-Oncology | Cardio-Oncology program in Australia |
| 15.00 – 15.20 | Mariana Mirabel Communications Coordinator, ESC Council of Cardio-Oncology | Do new cancer therapies mean lower cardiovascular toxicity? My daily practice in France |
| 15.20 – 15.40 | Dimitrios Farmakis Liaison Officer, ESC Council of Cardio-Oncology | Arrhythmias in cardio-oncology |
| 15.40 – 16.00 | Pietro Ameri Secretary, ESC Council of Cardio-Oncology | Basic science in cardio-oncology |
16:00 – 17:30
Session V – under patronage of the Maria Skłodowska-Curie National Research Institute of OncologyChairs: Mariana Mirabel, Pietro Ameri | ||
| 16.00 – 16.15 | Jakub Kucharz | Experiences from Uro-Oncology |
| 16.15 – 16.30 | Daniel Lenihan Past President of the International Cardio-Oncology Society | Modern Detecting Early Myocardial Injury |
| 16.30 – 16.45 | Patrycja Ozdowska | Experiences from ECHO Lab |
| 16.45 – 17.00 | Sławomir Blamek | Experiences of Radiotherapists |
| 17.00 – 17.15 | Alexander Lyon Past Chair of the ESC Council of Cardio-Oncology (2022-2024) | Cardio-Oncology at the Royal Brompton Hospital – ESC guidelines and research directions |
| 17.15 – 17.30 | Sebastian Szmit Chair of Study Group on Thrombosis, ESC Council of Cardio-Oncology (2024-2026) | Venous thromboembolism – ESC guidelines and research directions |
17:30 – 17:45
Conference Closing / Summary and Recommendations
Announcement of Plans for 2026
Acknowledgements and Certificates of Participation
Organisers and Partners
Patronage
Media Patron
